

Cite this: *Chem. Sci.*, 2024, 15, 14310

All publication charges for this article have been paid for by the Royal Society of Chemistry

Probing the formation of a hetero-dimeric membrane transport complex with dual *in vitro* and *in silico* mutagenesis†

Nishadh Rathod,^a M. Joanne Lemieux,^a Christophe Chipot,^{bcd} Benoît Roux^b and Howard S. Young^{*a}

The reversible association of transmembrane helices is a fundamental mechanism in how living cells convey information and respond to physiological events. The cardiac calcium transport regulator phospholamban (PLN) is an example of a single-span transmembrane protein that populates a variety of reversible and competing oligomeric states. PLN primarily forms monomers and pentamers in the membrane, where the PLN pentamer is a storage form and the PLN monomer forms a hetero-dimeric inhibitory complex with SERCA. The binding affinity and free-energy of formation of the SERCA-PLN complex in a membrane have not been determined. As is the case for most transmembrane protein interactions, measuring these quantities experimentally is extremely challenging. In this study, we estimated binding affinities by employing *in silico* alchemical free-energy calculations for all PLN transmembrane alanine substitutions in a membrane bilayer. The binding affinities were calculated separately for the SERCA-PLN complex, a PLN monomer, and a PLN pentamer and compared to *in vitro* functional measurements of SERCA regulation by the PLN alanine substitutions. Initially, the changes in SERCA inhibition by PLN alanine substitutions were compared to the changes in free energy for the SERCA-PLN complex formed from the PLN monomer. However, the functional data for the PLN alanine substitutions were better explained by the formation of the SERCA-PLN complex directly from the PLN pentamer. This finding points to an inhibitory mechanism favoring conformational selection of SERCA and the interaction of a PLN pentamer with SERCA for 'delivery' of a PLN monomer to the inhibitory site. The implications of these findings suggest that the energetics of helix exchange between homo- and hetero-oligomeric signaling complexes is favored over an intermediate involving a free monomeric helix in the membrane bilayer.

Received 2nd May 2024
Accepted 5th August 2024

DOI: 10.1039/d4sc02915a

rsc.li/chemical-science

Introduction

Transmembrane helix–helix interactions play a critical role in the folding, function, assembly, and oligomerization of many proteins. The reversible association of transmembrane helices is a fundamental mechanism in cellular signaling and how living cells convey information and respond to physiological events. While there are many single-pass transmembrane proteins that undergo reversible helix–helix interactions, some

examples involved in signaling include the receptor tyrosine kinases, STIM proteins (stromal interaction molecule 1 & 2), and cadherins among many others. In these processes, the diversity of transmembrane helix interactions ranges from monomeric transmembrane helices in a lipid bilayer to helix–helix interactions that include both homo- and hetero-oligomeric complexes. The equilibrium between single transmembrane helices in a lipid bilayer and helix–helix interactions favors helix–helix association because transmembrane helices and their apolar side chains pack more efficiently with other transmembrane helices than they do with lipid acyl chains in the membrane bilayer.¹ The competing effects of favorable helix–helix interactions and unfavorable helix–lipid interactions can contribute to helix self-association *via* a combination of favorable van der Waals interactions, hydrogen bonding, electrostatic interactions, and unfavorable lipophobic effects.^{2,3}

An example of a single-span transmembrane protein that populates a variety of reversible and competing association states (*i.e.*, monomer, homo-oligomer, hetero-oligomer) is the cardiac calcium transport regulatory peptide phospholamban

^aDepartment of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2H7. E-mail: hyoung@ualberta.ca; Fax: +1 (780) 492-3931; Tel: +1 (780) 492-3931

^bDepartment of Biochemistry and Molecular Biology, University of Chicago, Chicago, USA 60637

^cLaboratoire International Associé Centre National de la Recherche Scientifique et University of Illinois at Urbana-Champaign, Unité Mixte de Recherche no. 7019, Université de Lorraine, B.P. 70239, 54506 Vandœuvre-lès-Nancy Cedex, France

^dTheoretical and Computational Biophysics Group, Beckman Institute, Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4sc02915a>



(PLN). PLN regulates the sarco-endoplasmic reticulum calcium ATPase (SERCA). SERCA is ubiquitously expressed in all eukaryotic cells, where it actively transports calcium ions from the cytosol to the lumen of the sarco-endoplasmic reticulum (SR/ER) against a concentration gradient.⁴ The structure of SERCA includes three cytoplasmic domains, the nucleotide-binding (N), phosphorylation (P), and actuator (A) domains, as well as ten transmembrane helices. SERCA progresses through an elaborate transport cycle that involves two main states, a calcium-bound E1 state and a calcium-free E2 state.^{5,6} PLN is a 52 amino acid transmembrane peptide that physically interacts with SERCA and regulates calcium transport activity (Fig. 1A). It is primarily expressed in ventricular muscle^{7,8} and mutations in the *PLN* gene are implicated in cardiomyopathies and heart failure.^{9–14} The structure of PLN includes an N-terminal cytoplasmic helix (residues 1–17), a short linker region (residues 18–25) and a transmembrane helix (residues 26–52). The transmembrane domain of PLN is primarily responsible for inhibiting the activity of SERCA, while the cytoplasmic domain of PLN is primarily responsible for regulating SERCA inhibition *via* phosphorylation (Ser¹⁶ & Thr¹⁷) and the β -adrenergic signaling pathway.

The model for SERCA inhibition by PLN involves a PLN monomer binding to the transmembrane domain of SERCA involving transmembrane segments M2, M6, and M9 (heterodimeric SERCA-PLN complex; Fig. 1B). PLN inhibition of

SERCA manifests as a change in the apparent calcium affinity (K_{Ca}) of SERCA such that the SERCA-PLN complex has lower affinity for calcium.^{8,15} By itself, PLN also forms a pentamer, which is suggested to be an inactive storage form of PLN in the membrane (homo-oligomeric PLN-PLN complex). The PLN pentamer is stabilized by a leucine-isoleucine zipper composed of residues Ile³³, Leu³⁷, Ile⁴⁰, Leu⁴⁴, Ile⁴⁷ and Leu⁵¹.¹⁶ The model for SERCA regulation suggests that the PLN pentamer is in dynamic equilibrium with the PLN monomer, and the PLN monomer then associates with SERCA to cause inhibition.^{17–19} Thus, the helix-lipid and helix-helix interactions involved in this regulatory mechanism include an “active” PLN monomer in the membrane bilayer, a homo-pentameric PLN “storage” species, and an “inhibited” hetero-dimeric SERCA-PLN complex. However, the kinetics of monomer release from the PLN pentamer is slow (second timescale²⁰) relative to the physiological window for formation of the inhibitory SERCA-PLN complex (millisecond timescale). Thus, the mechanism by which a PLN monomer transitions from the helix-helix interactions that stabilize the pentamer to the helix-helix interactions that stabilize the SERCA-PLN inhibitory complex still remains elusive.

The structure of the SERCA-PLN complex has been determined by X-ray crystallography.^{21–23} Despite this advance, the binding affinity and free-energy of formation of the SERCA-PLN complex in a membrane environment have not been determined. While measuring these quantities experimentally is extremely challenging, binding affinities can be estimated using *in silico* methods for free-energy calculations ($\Delta G_{\text{binding}}$). Although, widespread application has been limited by the availability of computational resources. The recent offloading of free-energy perturbation (FEP) and thermodynamic integration (TI)²⁴ calculations on GPUs in the NAMD simulation software^{25,26} has made these approaches more affordable and efficient, which is necessary for investigating membrane protein complexes. In this work, we carried out *in silico* alchemical free-energy perturbation calculations for all transmembrane alanine substitutions in PLN (from Ile¹⁸-Ala to Leu⁵²-Ala). This was done in a lipid membrane for the SERCA-PLN complex, as well as the PLN monomer and PLN pentamer. We compared the simulation data to the *in vitro* functional analysis of the PLN alanine substitutions and their ability to inhibit SERCA. The PLN variants were classified for their ability to alter the apparent calcium affinity of SERCA (*i.e.* K_{Ca} parameters for SERCA). Loss-of-function PLN variants did not inhibit SERCA and gain-of-function PLN variants were super-inhibitors of SERCA. The changes in SERCA inhibition by PLN variants were compared to the changes in free energy ($\Delta\Delta G$) for the formation of the SERCA-PLN complex from either the PLN monomer or the PLN pentamer. The functional data for the PLN variants were better explained by the formation of the SERCA-PLN complex directly from the PLN pentamer. This suggests an inhibitory mechanism that favors the interaction of a PLN pentamer with SERCA for the ‘delivery’ of a PLN monomer to the inhibitory site and selection of the appropriate conformation of SERCA.




Fig. 1 Topology diagram for phospholamban (PLN) and structure of the SERCA-PLN complex. (A) The transmembrane domain is colored grey and the residues studied are circled in black. The leucine-isoleucine residues of PLN that are involved in pentamer formation are circled in grey. (B) Structure of SERCA-PLN complex (PDB: 4KYT) in cartoon format. PLN is shown as cyan. SERCA transmembrane domain is tan, transmembrane segments M4 and M5 are blue, the N domain is green, the P domain is magenta, and the A domain is yellow.






Fig. 2 Changes in the apparent calcium affinity of SERCA in the presence of the alanine substitutions of PLN. To better delineate the changes in the apparent calcium affinity (K_{Ca}) of SERCA, we calculated ΔK_{Ca} for each alanine substitution. The ΔK_{Ca} values were calculated as the difference between the K_{Ca} value for the alanine substitution and the K_{Ca} value for SERCA in the presence of wild-type PLN. Negative ΔK_{Ca} values indicate loss-of-function variants that are weaker inhibitors of SERCA (e.g. N34A; SERCA has a higher affinity for calcium in the presence of this variant compared to wild-type PLN) and positive ΔK_{Ca} values indicate gain-of-function variants that are more potent inhibitors of SERCA (e.g. I47A; SERCA has a lower affinity for calcium in the presence of this variant compared to wild-type PLN). Error bars indicate SEM ($n \geq 4$). Statistical significance for the K_{Ca} values is shown as asterisks (*) as in Fig. S1† ($p < 0.01$).

Results and discussion

Loss- and gain-of-function variants of PLN were initially reported based on alanine-scanning mutagenesis of PLN and SERCA functional measurements (e.g. ref. 17, 19 and 27). Loss-of-function variants were thought to disrupt physical interactions between PLN and SERCA that are required for inhibition. Based on the observation of PLN oligomeric states by SDS-PAGE, gain-of-function variants were thought to disrupt the PLN pentamer and lead to an increased concentration of monomers in the membrane that ultimately caused super-inhibition of SERCA.^{19,28} In this model for SERCA inhibition by PLN, the PLN pentamer releases a monomer, the monomer diffuses through the membrane until it encounters SERCA, and the monomer binds to SERCA and forms the inhibitory complex. However, as stated above, the slow kinetics for monomer release from the PLN pentamer is seemingly inconsistent with the faster timescale for SERCA conformational changes and PLN inhibition.²⁰

With this in mind, the primary objective of this study was to compare changes in free energy ($\Delta\Delta G$), which reflect changes in binding affinity of PLN for SERCA, with the loss-of-function or gain-of-function behavior of PLN alanine substitutions. The expectation was that PLN loss-of-function variants will have lower binding affinity for SERCA ($\Delta\Delta G > 0$), while PLN gain-of-function variants will have higher binding affinity for SERCA ($\Delta\Delta G < 0$). The hypothesis we aimed to test was the formation of the SERCA-PLN complex from a PLN monomer. Towards this end, we performed alanine-scanning mutagenesis and functional analysis of PLN residues Ile¹⁸-Ala to Ile³³-Ala using an *in vitro* membrane reconstitution system to determine the apparent calcium affinity (K_{Ca}) of SERCA in the presence of the PLN alanine variants. The remaining mutagenesis data included in this study for PLN residues Asn³⁴-Ala to Leu⁵²-Ala has been previously published.^{15,29} These functional data were then compared to *in silico* alanine-scanning mutagenesis of PLN using alchemical free-energy simulations and determination of $\Delta\Delta G$ for each alanine variant.



Apparent calcium affinity (K_{Ca}) of SERCA

SERCA was reconstituted into membrane vesicles (proteoliposomes) in the absence and presence of the PLN variants as previously described.^{15,29,30} Functional characterization of the proteoliposomes was assessed by the measurement of calcium-dependent ATPase activity of SERCA alone (negative control), SERCA in the presence of wild-type PLN (positive control), and SERCA in the presence of the PLN alanine variants. This activity assay has been validated against calcium transport measurements.³¹ The ATPase activity data were plotted as log calcium concentration *versus* specific activity, and the apparent calcium affinity (K_{Ca}) of SERCA was determined as the calcium concentration for half-maximal SERCA activity (Fig. S1 and Table S1†). This approach has been well-established for comparing K_{Ca} measurements between different variants of PLN (*e.g.* see ref. 14, 15, 29 and 30). To evaluate the status of the alanine substitutions relative to wild-type PLN, the K_{Ca} value determined for SERCA in the presence of wild-type PLN (K_{Ca} of 0.88 μM calcium) was subtracted from the K_{Ca} values determined for SERCA in the presence of the PLN variants (ΔK_{Ca} ; Fig. 2). This was done for alanine substitutions Ile¹⁸-Ala to Ile³³-Ala characterized in this study and Asn³⁴-Ala to Leu⁵²-Ala previously published.^{15,29}

Based on the ΔK_{Ca} values, the alanine variants were categorized as loss of function ($\Delta K_{Ca} < 0$; loss of SERCA inhibition), neutral ($\Delta K_{Ca} \approx 0$), or gain of function ($\Delta K_{Ca} > 0$; gain of SERCA inhibition). The dominant characteristic of the alanine variants was loss of function. The Asn³⁴-Ala was the most severe loss-of-function variant, completely eliminating SERCA regulation by PLN.^{15,19} The K_{Ca} value determined for SERCA in the presence of wild-type PLN was 0.88 μM calcium compared to 0.45 μM calcium for SERCA in the presence of Asn³⁴-Ala PLN (ΔK_{Ca} of -0.43). Another severe loss-of-function variant of PLN was Ile³⁸-Ala (ΔK_{Ca} of -0.39). In total, 14 alanine variants of PLN resulted in K_{Ca} (Fig. S1 and Table S1†) and ΔK_{Ca} (Fig. 2) values that were indicative of loss of function (K_{Ca} values ranging from 0.45 for Asn³⁴-Ala to 0.66 for Leu³¹-Ala & Cys⁴⁶-Ala; ΔK_{Ca} values ranging from -0.43 to -0.22 , respectively). Based on the crystal structure of the SERCA-PLN complex, most of these residues line the helical face of PLN that interacts with the inhibitory groove of SERCA.

In addition to the loss-of-function variants, a subset of alanine variants resulted in gain of function and more potent inhibition of SERCA (Fig. 2). The Leu³⁷-Ala and Ile⁴⁷-Ala were the most potent gain-of-function variants, markedly increasing SERCA inhibition relative to wild-type PLN. Compared to SERCA in the presence of wild-type PLN (K_{Ca} of 0.88 μM calcium), the Leu³⁷-Ala and Ile⁴⁷-Ala variants of PLN were super-inhibitors of SERCA (K_{Ca} of 1.57 and 1.87 μM calcium; ΔK_{Ca} of 0.69 and 0.99, respectively). Three other substitutions – Ile³³-Ala, Leu⁴³-Ala, and Leu⁴⁴-Ala – were also more potent inhibitors of SERCA (ΔK_{Ca} of 0.28, 0.34, and 0.23, respectively). Finally, four additional substitutions resulted in mild gain of function – Met²⁰-Ala, Lys²⁷-Ala, Cys³⁶-Ala, and Leu⁵¹-Ala (ΔK_{Ca} of 0.09, 0.12, 0.09, and 0.12, respectively). In the crystal structure of the SERCA-PLN complex, most of these residues line the helical face of




Fig. 3 Thermodynamic cycle describing the free energy of formation of the SERCA-PLN complex from the PLN monomer (A) or PLN pentamer (B). SERCA is shown in grey cartoon format, wild-type PLN in blue, and the alchemically transformed residues of PLN in red. Alchemical transformations were performed for alanine substitution of each residue in PLN in a lipid bilayer ($\Delta G_{\text{unbound-alchemical}}$) and in the SERCA-PLN complex in a lipid bilayer ($\Delta G_{\text{bound-alchemical}}$). The top horizontal process in each panel corresponds to the free energy for binding of SERCA to wild-type PLN ($\Delta G_{\text{wt-binding}}^{\circ}$) and the bottom horizontal process corresponds to the free energy for binding of SERCA to an alanine-substitution PLN ($\Delta G_{\text{mut-binding}}^{\circ}$). The left vertical process in each panel corresponds to the free energy for alchemically mutating a single residue in PLN to alanine in the unbound state ($\Delta G_{\text{unbound-alchemical}}$). The right vertical process in each panel corresponds to free energy for alchemically mutating a single residue in PLN to alanine in a SERCA-bound complex ($\Delta G_{\text{bound-alchemical}}$). The difference in the vertical processes equates to the difference in horizontal processes ($\Delta\Delta G$). The ΔG and $\Delta\Delta G$ values are presented herein for all alanine substitutions of PLN from Ile¹⁸-Ala to Leu⁵²-Ala (ESI Tables 1 and 2†). The $\Delta\Delta G$ values for the formation of the SERCA-PLN complex from the PLN monomer are shown in Fig. 4A. The $\Delta\Delta G$ values for the formation of the SERCA-PLN complex from the PLN pentamer are shown in Fig. 4B.






Fig. 4 The $\Delta\Delta G$ values derived from the thermodynamic cycle for (A) formation of the SERCA-PLN complex from the PLN monomer (Fig. 3A) and (B) formation of the SERCA-PLN complex from the PLN pentamer (Fig. 3B). The $\Delta\Delta G$ values (kcal mol^{-1}) were calculated as the difference between the SERCA-PLN complex ($\Delta G_{\text{bound-alchemical}}$) and the PLN monomer (A) or PLN pentamer (B) in a lipid bilayer ($\Delta G_{\text{unbound-alchemical}}$). Negative $\Delta\Delta G$ values (kcal mol^{-1}) indicated alanine substitutions that have higher affinity for SERCA compared to wild-type PLN (e.g., R25A). Positive $\Delta\Delta G$ values (kcal mol^{-1}) indicated alanine substitutions that have lower affinity for SERCA compared to wild-type PLN (e.g., I38A). The FEP values and associated errors were determined using ParseFEP and indicate Bennett Acceptance Ratio (BAR) free-energy estimates between the forward and backward transformations.

PLN that is oriented away from the inhibitory groove of SERCA, with the exception of Lys²⁷ and Met²⁰.

Formation of the SERCA-PLN complex from a PLN monomer

Our next objective was to determine the changes in binding affinity for SERCA that accompany alanine substitution of each residue in PLN (Ile¹⁸-Ala to Leu⁵²-Ala). To estimate binding affinities, we used the *in silico* method of alchemical free-energy simulations to determine the difference in free energy of binding for each of the alanine variants compared to wild-type PLN in the SERCA-PLN complex.²¹ The thermodynamic cycle for binding of a PLN monomer to SERCA and the alchemical transformations are shown in Fig. 3A. The thermodynamic cycle includes the formation of the SERCA-PLN complex from a PLN monomer for wild-type ($\Delta G_{\text{wt-binding}}^{\circ}$) and the alanine variants ($\Delta G_{\text{mut-binding}}^{\circ}$). The free-energy calculations in the thermodynamic cycle include alchemical transformation of the SERCA-bound complex ($\Delta G_{\text{bound-alchemical}}$) and the unbound PLN monomer ($\Delta G_{\text{unbound-alchemical}}$) in a membrane environment. We determined $\Delta G_{\text{bound-alchemical}}$ and $\Delta G_{\text{unbound-alchemical}}$ (Table

S1†) using the alchemical free-energy perturbation method. The change in free energy of formation for the PLN variant ($\Delta G_{\text{mut-binding}}^{\circ}$ minus $\Delta G_{\text{wt-binding}}^{\circ}$) was equivalent to the difference in free energy between the bound and unbound alchemical transformations ($\Delta\Delta G = \Delta G_{\text{bound-alchemical}}$ minus $\Delta G_{\text{unbound-alchemical}}$).

The $\Delta\Delta G$ value for each PLN variant was indicative of higher affinity binding ($\Delta\Delta G < 0$), neutral ($\Delta\Delta G \approx 0$), or lower affinity binding ($\Delta\Delta G > 0$) to SERCA (Fig. 4A and Table S2†). A group of variants resulted in negative $\Delta\Delta G$ values indicative of higher affinity binding to SERCA (15 variants). The largest negative changes in $\Delta\Delta G$ were for Glu¹⁹-Ala, Gln²³-Ala, Arg²⁵-Ala, Asn³⁰-Ala, Ile³³-Ala, and Met⁵⁰-Ala. Additional residues also exhibited negative changes in $\Delta\Delta G$ that were statistically significant but lower in magnitude by comparison (Fig. 4A). Another group of variants resulted in positive $\Delta\Delta G$ values indicative of lower affinity binding to SERCA (13 variants). The largest positive changes in $\Delta\Delta G$ were for Asn³⁴-Ala, Ile³⁸-Ala, and Ile⁴⁸-Ala. Additional residues also exhibited positive changes in $\Delta\Delta G$ that were statistically significant but lower in magnitude by






Fig. 5 Scatter plots of $\Delta\Delta G$ (kcal mol^{-1}) versus ΔK_{Ca} (μM) for each alanine substitution in PLN and the thermodynamic cycle from the PLN monomer (A) and thermodynamic cycle for the PLN pentamer (B). The expected regions are highlighted in green. Top left quadrant corresponds to alanine variants that have lower binding affinity for SERCA and result in loss of function compared to wild-type PLN (e.g., N34A). The bottom right quadrant corresponds to alanine variants that have higher binding affinity for SERCA and result in gain of function compared to wild-type PLN (e.g., L37A). The top right quadrant corresponds to alanine variants that have lower binding affinity for SERCA and result in gain of function compared to wild-type PLN. The bottom left quadrant corresponds to alanine variants that have higher binding affinity for SERCA and result in loss of function compared to wild-type PLN (e.g., R25A). Error bars indicate SEM for ΔK_{Ca} ($n \geq 4$) and $\Delta\Delta G$ (BAR estimator implemented in ParseFEP). A linear regression fit is shown for each plot and the R values are indicated. Note that E19A, R25A, Q23A, and M50A were excluded from the regression fit because of their distinct behavior.

comparison (Fig. 4A). However, the calculation of the $\Delta\Delta G$ values depended on the chemical state of PLN, which in this thermodynamic cycle was a PLN monomer embedded in a lipid

bilayer (Fig. 3A). Thus, determining the free-energy change between the bound and unbound states ($\Delta\Delta G = \Delta G_{\text{bound-alchemical}}$ minus $\Delta G_{\text{unbound-alchemical}}$) provided insights into the formation of the SERCA-PLN complex from a PLN monomer in a membrane environment.

To understand the effect of alanine variants on formation of the SERCA-PLN complex from the PLN monomer, we plotted $\Delta\Delta G$ (kcal mol^{-1}) versus ΔK_{Ca} (μM calcium) for all variants (Fig. 5A). The objective was to correlate the changes in binding affinity (negative or positive changes in $\Delta\Delta G$) with the loss-of-function or gain-of-function behavior of the alanine variants (negative or positive changes in ΔK_{Ca}). The expectation was that loss-of-function variants ($\Delta K_{\text{Ca}} < 0$) should correlate with a lower binding affinity for SERCA ($\Delta\Delta G > 0$) and gain-of-function variants ($\Delta K_{\text{Ca}} > 0$) should correlate with a higher binding affinity for SERCA ($\Delta\Delta G < 0$). Reduced binding of PLN to the inhibitory groove of SERCA should result in reduced inhibition and more efficient SERCA calcium transport. Similarly, increased binding of PLN to the inhibitory groove of SERCA should result in increased inhibition and less efficient SERCA calcium transport. This pattern fit many of the residues such as the most severe loss-of-function variants Asn³⁴-Ala and Ile³⁸-Ala (Fig. 5A; upper left quadrant), and gain-of-function variants such as Ile³³-Ala, Leu⁴³-Ala, and Leu⁴⁴-Ala (Fig. 5A; lower right quadrant). However, there were some clear deviations from this pattern. Some loss-of-function variants were predicted to have higher affinity for SERCA, such as Glu¹⁹-Ala, Gln²³-Ala, Arg²⁵-Ala, and Met⁵⁰-Ala (Fig. 5A; lower left quadrant). At first this seems implausible; however, it is interesting to consider that these latter variants lie at the membrane surfaces, where higher affinity binding might alter the way the transmembrane domain of PLN crosses the membrane bilayer and interacts with SERCA. Since SERCA inhibition depends on the orientation of PLN in the inhibitory groove,³² higher affinity binding could result in a non-productive complex and loss of function.

From this comparison, there were several variants that remained difficult-to-explain outliers, particularly Lys²⁷-Ala, Leu³⁷-Ala, and Ile⁴⁷-Ala. The Lys²⁷-Ala variant is a well-known gain-of-function variant,^{15,27,33} yet the formation of the SERCA-PLN complex from the PLN monomer predicted this variant to have a lower affinity for SERCA (Fig. 5A; upper right quadrant). It seemed implausible that a PLN variant can result in both gain of function and lower affinity for SERCA. In addition, the two most potent super-inhibitors of SERCA, gain-of-function variants Leu³⁷-Ala and Ile⁴⁷-Ala (Fig. 2), did not appreciably alter the binding affinity for SERCA (Fig. 5A). These latter two residues, Leu³⁷ and Ile⁴⁷, have been reported to both stabilize the PLN pentamer and physically interact with SERCA.³⁴ Thus, the hypothesis for formation of the SERCA-PLN complex from a PLN monomer did not explain the results for this subset of gain-of-function alanine variants of PLN.

Formation of the SERCA-PLN complex from a PLN pentamer

Since the formation of the SERCA-PLN complex from a PLN monomer did not explain some gain-of-function variants of PLN, we considered an alternative hypothesis for the formation






Fig. 6 Overlay of the scatter plots of $\Delta\Delta G$ (kcal mol^{-1}) versus ΔK_{Ca} for each alanine substitution in PLN and the thermodynamic cycle from the PLN monomer (black circles) and PLN pentamer (grey circles). This figure is an overlay of Fig. 5A and B. Notice the better fit between the $\Delta\Delta G$ and ΔK_{Ca} values for the thermodynamic cycle from the PLN pentamer including alanine substitutions K27A, L37A, L43A, L44A, I47A, and L51A. Statistical analysis was performed using an independent samples *t*-test (* $p < 0.02$; ** $p < 0.01$).

of the SERCA-PLN complex from a PLN pentamer. As above, our objective was to determine how the alanine-scanning mutagenesis of PLN and SERCA functional measurements (ΔK_{Ca}) compared with changes in the binding affinity of PLN for SERCA ($\Delta\Delta G$). The thermodynamic cycle for formation of the SERCA-complex directly from the PLN pentamer using *in silico* alchemical free-energy simulations is shown in Fig. 3B. The thermodynamic cycle includes the formation of the SERCA-PLN complex from a PLN pentamer for wild-type ($\Delta G_{wt-binding}^\circ$) and alanine variants ($\Delta G_{mut-binding}^\circ$). Analogous to Fig. 3A, the free-energy calculations in the thermodynamic cycle included the alchemical transformation of the SERCA-PLN complex ($\Delta G_{bound-alchemical}$) and the PLN pentamer in a membrane environment ($\Delta G_{unbound-alchemical}$). The unbound state in this thermodynamic cycle was the PLN pentamer in a membrane environment, where each residue may be involved in PLN-PLN and/or PLN-lipid interactions. We determined $\Delta G_{bound-alchemical}$ and $\Delta G_{unbound-alchemical}$ (Table S1†) using the alchemical free-energy perturbation method. As described above, the change in free energy of formation for the PLN variant ($\Delta G_{mut-binding}^\circ$ minus $\Delta G_{wt-binding}^\circ$) was equivalent to the difference in free energy between the bound and unbound alchemical transformations ($\Delta\Delta G = \Delta G_{bound-alchemical}$ minus $\Delta G_{unbound-alchemical}$; Fig. 4B).

For a comparison of the effect of alanine variants on formation of the SERCA-PLN complex from the PLN pentamer, we plotted $\Delta\Delta G$ (kcal mol^{-1}) versus ΔK_{Ca} (μM calcium) for all variants (Fig. 5B). As described above, the gain-of-function variants that remained unexplained, Lys²⁷-Ala, Leu³⁷-Ala, and Ile⁴⁷-Ala, were better fit by the thermodynamic cycle involving the PLN pentamer. In fact, many of the gain-of-function variants were better explained (lower $\Delta\Delta G$ values) by formation of the




Fig. 7 Structure of SERCA-PLN complex (PDB: 4KYT). (A) PLN is shown as cyan cartoon format. SERCA transmembrane domain is tan, transmembrane segments M4 and M5 are blue, the N domain is green, the P domain is magenta, and the A domain is yellow in cartoon format. The alanine substitutions labeled in Fig. 5B are shown for the three main quadrants: (B) lower affinity for SERCA, loss of function (N34A, F35A, I38A); (C) high affinity for SERCA, gain of function (K27A, I33A, L37A, L43A, L44A, I47A, L51A); and (D) higher affinity for SERCA, loss of function (E19A, R25A, Q29A, M50A). These residues are shown in sphere representation. (E) Scheme depicting relative energy states for the SERCA-PLN complex formed from the PLN monomer and PLN pentamer, as well as the release of a PLN monomer from the PLN pentamer. Arrows indicate the transitions between the different states. SERCA is shown in grey cartoon format and PLN is shown in blue.

SERCA-PLN complex from the PLN pentamer, including residues Lys²⁷-Ala, Leu³⁷-Ala, Leu⁴³-Ala, Leu⁴⁴-Ala, Ile⁴⁷-Ala, and Leu⁵¹-Ala (Fig. 6). Most of these residues, with the exception of Lys²⁷, were shown to be part of the Leu-Ile zipper involved in formation of the PLN pentamer.^{16,19} Furthermore, the $\Delta\Delta G$ values for super-inhibitory variants increased in magnitude in the formation of the SERCA-bound complex from the PLN pentamer indicating an improved correlation using this thermodynamic cycle as compared to the thermodynamic cycle involving the PLN monomer. As notable examples, the $\Delta\Delta G$



values decreased for Leu³⁷-Ala ($-0.7 \rightarrow -2.3 \text{ kcal mol}^{-1}$), Leu⁴⁴-Ala ($-1.4 \rightarrow -4.6 \text{ kcal mol}^{-1}$), and Ile⁴⁷-Ala ($0.0 \rightarrow -2.6 \text{ kcal mol}^{-1}$) indicating a better fit by the thermodynamic cycle involving the PLN pentamer. Unlike the model involving the PLN monomer (Fig. 3A), only a single variant, Met²⁰-Ala, resulted in mild gain of function ($\Delta K_{\text{Ca}} > 0$) and lower affinity for SERCA ($\Delta\Delta G > 0$). Since Met²⁰ is not part of the transmembrane domain of PLN, perhaps it is not surprising that this variant was not fit well by either thermodynamic cycle.

It is interesting to consider the structure of the SERCA-PLN complex (Fig. 7) and the location of key residues implicated in the formation of the SERCA-PLN complex from the PLN pentamer. Residues that exhibited *lower* affinity for SERCA and PLN *loss* of function included Asn³⁴-Ala (N34A), Phe³⁵-Ala (F35A), and Ile³⁸-Ala (I38A). These residues face the inhibitory groove of SERCA (Fig. 7B). Residues that exhibited *higher* affinity for SERCA and PLN *gain* of function included Lys²⁷-Ala (K27A), Ile³³-Ala (I33A), Leu³⁷-Ala (L37A), Leu⁴³-Ala (L43A), Leu⁴⁴-Ala (L44A), Ile⁴⁷-Ala (I47A), and Leu⁵¹-Ala (L51A). Except for Lys²⁷-Ala, these residues are peripheral to the inhibitory groove of SERCA (Fig. 7C). Finally, residues that exhibited *higher* affinity for SERCA and PLN *loss* of function included Glu¹⁹-Ala (E19A), Arg²⁵-Ala (R25A), Gln²⁹-Ala (Q29A), and Met⁵⁰-Ala (M50A). While this was an unexpected behavior, these residues lie at the membrane surfaces suggesting that they play a role in orienting PLN in the inhibitory groove of SERCA (Fig. 7D).

Conformational selection of SERCA by the PLN pentamer

Cellular signaling events are often mediated by the lateral association of membrane proteins that change state in response to chemical signals. Membrane protein self-association and helix-helix interactions make up a significant structural feature of the cellular signaling landscape. Despite the clear importance of membrane protein interactions, the measurement of binding affinities in a membrane environment has been challenging. To address this problem, we studied the interaction between PLN and SERCA using an *in vitro* functional assay and *in silico* computational approach. PLN was an attractive choice for the following reasons. First, there is a large amount of functional data for SERCA in the presence of PLN alanine variants.^{15,19,29} Second, PLN adopts a variety of helical association states in the membrane including a free monomer, a homo-pentameric state, and a hetero-oligomeric state when bound to SERCA. Third, there is an established model for SERCA regulation by PLN, where the PLN pentamer is in dynamic equilibrium with the PLN monomer, and the PLN monomer is the species that interacts with and inhibits SERCA.¹⁷⁻¹⁹ Finally, there are structures available for the dominant states including the SERCA-PLN complex,²¹ the PLN monomer,³⁵ and the PLN pentamer.³⁶

The objective was to understand the free-energy changes that accompany helix-helix association in a membrane environment. To the best of our knowledge, this would be the first application of this method to a membrane protein complex. In the thermodynamic cycle for formation of the SERCA-PLN inhibitory complex (Fig. 3), the free-energy changes were

calculated as the difference between the bound and unbound states. The SERCA-PLN complex was the bound state and the PLN monomer was the unbound state. This gave rise to a set of free-energy changes calculated for the array of PLN variants (Table S2† and Fig. 4). To reconcile these free-energy changes, we compared the $\Delta\Delta G$ values with the apparent calcium affinity (K_{Ca}) determined for SERCA in the presence of each PLN alanine substitution (Fig. 5). The expectation was changes in binding affinity ($\Delta\Delta G$) of the PLN monomer should correlate with changes in function (ΔK_{Ca}), consistent with the existing model for SERCA regulation.

Although we expected our findings to support SERCA regulation by the PLN monomer, the free-energy changes did not offer a satisfactory fit to the functional data for the PLN variants. This led us to consider a second unbound state, the PLN pentamer, which gave rise to a different set of free-energy changes calculated for the array of PLN variants (Table S2† and Fig. 6). Surprisingly, using the PLN pentamer as the unbound state gave rise to free-energy changes ($\Delta\Delta G$) that better fit the functional data (ΔK_{Ca}) (Fig. 6). This was particularly true for some of the gain-of-function variants of PLN, such as Lys²⁷-Ala (K27A), Leu³⁷-Ala (L37A), Leu⁴³-Ala (L43A), Leu⁴⁴-Ala (L44A), Ile⁴⁷-Ala (I47A), Leu⁵¹-Ala (L51A) (Fig. 6). To further test this finding, we turned to another set of experimental data previously published by the MacLennan laboratory.^{19,27,37} These data included K_{Ca} measurements for SERCA in the presence of alanine variants of canine PLN. The only difference in the sequence of residues considered was Asn²⁷ in canine PLN is Lys²⁷ in human PLN. It should be noted that there are substantial differences in the K_{Ca} values determined by us (Fig. S1† and ref. 29) and those previously published (Fig. 1 in ref. 37). Nonetheless, these data were also better correlated by the thermodynamic cycle involving the PLN pentamer (Fig. S2†). Therefore, we concluded that the data support a model for SERCA regulation where the SERCA-PLN complex can form *via* an interaction between SERCA and the PLN pentamer (Fig. 7E). Note that this does not exclude formation of the SERCA-PLN complex from the PLN monomer, though complex formation from the PLN pentamer is energetically more favorable.

There is evidence in the literature for an active role for the PLN pentamer in SERCA regulation,^{21,38-41} and it has become increasingly clear that the pentameric form of PLN is required for normal cardiac contractility.^{15,19,42-45} If the PLN pentamer plays a direct role in the formation of the SERCA-PLN complex, what is the underlying mechanism that favors formation of the SERCA-PLN complex from the pentamer? The transition from the PLN pentamer to the monomer, and then from the PLN monomer to the SERCA-PLN complex involves a series of distinct molecular interactions. Depending on the location in the transmembrane domain of PLN, a particular residue may interact with another PLN, lipids, SERCA, or some combination of the three. The free-energy changes ($\Delta\Delta G$) associated with these PLN states suggest that PLN-PLN interactions in the pentamer are a lower energy state and PLN-lipid interactions of the monomer are a higher energy state. By comparison, the free-energy changes associated with the SERCA-PLN complex suggest that it is an intermediate state between the PLN



pentamer and monomer. Thus, PLN-PLN and SERCA-PLN (helix-helix) interactions are favored over PLN-lipid (helix-lipid) interactions ($\Delta G_{\text{PLN-monomer}}^{\circ} > \Delta G_{\text{SERCA-PLN}}^{\circ} > \Delta G_{\text{PLN-pentamer}}^{\circ}$). However, some alanine variants of PLN shift the energy landscape of the PLN pentamer, though PLN-PLN and SERCA-PLN interactions are still favored over PLN-lipid interactions. Generally, these residues are part of the leucine-isoleucine zipper that stabilizes the pentameric form of PLN, where alanine substitution of these residues destabilizes the pentamer and increases the probability of monomer release. These alanine variants of PLN tend to be super-inhibitors of SERCA.

Does super-inhibition of SERCA by PLN alanine variants offer insights into the formation of the SERCA-PLN complex? The original model for SERCA inhibition by PLN involved the calcium-free E2 conformation of SERCA and an inhibitory groove formed by transmembrane segments M2, M6, and M9 of SERCA.^{46,47} The inhibitory groove is “open” in the calcium-free E2 state and “closed” in the calcium-bound E1 state of SERCA, where PLN was thought to bind to the “open” inhibitory groove and impede groove closure in the E2 to E1 transition. However, the subsequent crystal structures of the SERCA-PLN and SERCA-SLN complexes revealed a different conformation of SERCA poised in a calcium-free E1-like state.^{21–23} In the calcium free E1-like conformation of SERCA,²¹ the inhibitory groove is partially closed and intermediate between the open E2 and closed E1 states. This raises the notion of differential recognition of the “open” and partially “closed” inhibitory grooves by PLN. The partially closed inhibitory groove in the calcium-free E1-like conformation of SERCA is compatible with binding of the PLN pentamer, while the open inhibitory groove in the E2 state of SERCA is too deep and narrow to engage the PLN pentamer. Therefore, we suggest that formation of the SERCA-PLN inhibitory complex *via* the PLN pentamer allows for conformational selection of SERCA in the calcium-free E1-like state for the formation of the correct (physiological) complex. In this scenario, super-inhibition of SERCA may result from loss of conformational selection and the interaction of a PLN monomer with the open inhibitory groove in the E2 conformation of SERCA.

Conclusion: implications for transmembrane helix assembly

Single-pass transmembrane proteins can form a variety of homo- and hetero-oligomeric assemblies that induce, amplify, or mitigate cellular signaling events. The ability of homo- and hetero-oligomeric assemblies to sense cellular events (*e.g.*, changes in ion gradients or phosphorylation states) and change state are a fundamental feature of some cellular signaling systems. PLN is one example of a single-pass membrane protein that changes state from a homo-pentameric form to a hetero-oligomeric form with SERCA. The hetero-oligomeric interaction with SERCA results in SERCA inhibition, a shift in the apparent calcium affinity of SERCA, which is regulated by the phosphorylation of PLN and the cytosolic calcium concentration. The ability to transition from a homo-oligomeric state, the PLN pentamer, to a hetero-oligomeric state, the SERCA-PLN

complex, is a fundamental feature of this regulatory axis. The results of this study support the notion that the homo-oligomeric form of PLN directs the formation of the “correct” hetero-oligomeric SERCA-PLN complex. This conformational selection may be a general phenomenon in cellular signaling pathways that involve the transition between homo- and hetero-oligomeric transmembrane assemblies, where transmembrane helix-helix interactions are often dynamic and dependent on the functional state of the protein.

Experimental

Mutagenesis, expression, and purification of PLN

The protocol used for mutagenesis, expression and purification of PLN has been previously described.^{15,48} Residues Ile¹⁸ to Ile³³ of PLN were individually mutated to alanine. The remaining alanine-scanning mutagenesis data included in this study for PLN residues Asn³⁴-Ala to Leu⁵²-Ala has been published.^{15,29} Further details can be found in the ESI.†

Reconstitution of SERCA and PLN into proteoliposome

SERCA was purified from the SR of rabbit hind leg muscle and reconstituted into membrane vesicles (proteoliposomes) with purified recombinant human PLN as described.⁴⁹ Further details can be found in the ESI.†

Calcium-dependent ATPase activity assays

Proteoliposomes containing SERCA and PLN were then measured for their calcium-dependent ATPase activity using a coupled-enzyme assay as previously described.⁵⁰ Further details can be found in the ESI.†

Molecular modeling

Three different systems were prepared for *in silico* calculations. In the first system, the structure of the SERCA-PLN bound complex (PDB: 4KYT²¹) was used which contains three chains corresponding to one SERCA and two PLN. In this structure, the first PLN chain is in proximity to SERCA but only residues Pro21 to Val49 were resolved, while the second PLN chain was further away from SERCA and only residues Gln26 to Ile40 were resolved. All of the missing residues in the structure of SERCA as well as residues Ile18, Glu19, Met20, Met50, Leu51 and Leu52 in the first PLN chain were inserted using Modeller.⁵¹ For effective comparison to the functional data, differing residues were changed to the human PLN sequence. The second PLN chain was removed. This complex was embedded in a 256 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) pre-equilibrated lipid membrane box obtained from the CHARMM-GUI database.⁵² The acidic residues in the calcium-binding sites Glu771 and Glu908 were protonated while residues Glu309 and Asp800 were deprotonated based on PROPKA analysis.^{53,54} In the second and third systems, the structures of PLN monomer (PDB: 1FJK) and PLN pentamer (PDB: 2KYV), respectively, were embedded in the same lipid membrane box as above. In both PLN monomer and PLN pentamer, residues Met1 to Thr17 were removed and differing residues were changed to human wild-type sequence



using Modeller to keep the structures consistent for comparison.^{51,55–57} Each system was solvated and ionized with 0.15 M KCl using solvate and autoionize VMD plugins.⁵⁸ The protein structure file was generated using the VMD psfgen plugin⁵⁸ using CHARMM36 force field topology.^{59,60} For the alchemical free energy perturbation (FEP) simulations for alanine scanning mutagenesis, structures for different alanine mutants of the model systems were generated using a hybrid topology file in combination with AlaScan,⁶¹ psfgen and Mutator VMD plugins.⁵⁸

Molecular dynamics (MD) and free-energy perturbation (FEP) simulations

NAMD software^{25,26,62} was used to carry out all of the *in silico* simulations with NVIDIA P100 Pascal GPUs and CHARMM36 force field parameter files.^{59,60} Each of the three model systems, *i.e.*, SERCA-PLN complex, PLN monomer and PLN pentamer were first minimized, annealed, and equilibrated for overall 10 ns with unrestrained MD simulations prior to FEP calculations. The final dimension of all three systems upon equilibration were 110 Å × 110 Å × 150 Å. In the PLN pentamer system, alchemical FEP calculations in all five protomers were simultaneously performed and the stoichiometry was accounted for during the analysis step. Electrostatic and van der Waals cutoff distance was set to 11 Å with switching at 10 Å and pair list distance at 12 Å. Langevin piston pressure control was set to 1.01 bar and the temperature for Langevin calculations at 300 K. For periodic boundary conditions, the Particle Mesh Ewald method was applied for electrostatics and the wrapping of all coordinates was set to on. The alchemical FEP setup files were prepared using AlaScan⁶¹ with default parameters, the FEP calculation for each system was carried out with windows (λ) of width 0.05 or over 20 windows for forward transformation and the same procedure was repeated for the backward transformation. Each window consisted of 1×10^5 equilibration and 5×10^5 production steps of 1 fs each. The cumulative simulation time for each alanine alchemical FEP calculation was 24 ns. Alanine scanning FEP calculations for all residues in PLN from Ile18 to Leu52 (excluding Pro21) were performed separately and repeated for all three systems, SERCA-PLN complex, PLN monomer and PLN pentamer. The total cumulative simulation time was calculated to be 2.406 μ s [(33 alanine mutations × 3 systems × 24 ns) + (10 ns equilibration × 3 systems)]. Alchemical transformation free energy ($\Delta G_{\text{alchemical}}$) was determined from FEP simulation for each alanine mutation using VMD ParseFEP plugin with default settings^{58,63} (Fig. S3 and S4[†]). Subsequently, values for $\Delta G_{\text{bound-alchemical}}$ from SERCA-PLN complex system were subtracted for values from either the PLN monomer system or the PLN pentamer system ($\Delta G_{\text{unbound-alchemical}}$). This difference is equivalent to the difference in the free energy of formation of alanine-substituted SERCA-PLN complex compared to the wild-type SERCA-PLN complex ($\Delta\Delta G$). ParseFEP performs the alchemical transformations bidirectionally, and the results of the forward and backward simulations are combined in the form of the Bennett

acceptance-ratio (BAR) estimator of the free energy and statistical error (SEM).

To examine the effect of equilibration time on the initial structures of the model systems, the three model systems (SERCA-PLN complex, PLN monomer and PLN pentamer) were equilibrated for 10, 25, 40, and 50 ns of unrestrained MD simulations. Each of these equilibrated model systems were used as replicates for FEP calculations as described in the preceding paragraph. This was done for a subset of transmembrane residues including L37A, L43A, L44A, I47A, and L51A (Table S3[†]). The overall conclusions were further supported by these calculations, showing a clear preference for the thermodynamic cycle from the PLN pentamer (Fig. 3B).

Data availability

Data for this article, including the ParseFEP log files, are available at Borealis-Dataverse at <https://borealisdata.ca/dataset.xhtml?persistentId=doi:10.5683/SP3/7CKZYG>. All other data supporting this article have been included as part of the main article or ESI.[†]

Author contributions

Conceptualization – NR, MJL, CC, BR, HSY; methodology – NR, CC, BR, HSY; investigation – NR, HSY; visualization – NR, HSY; supervision – HSY; writing – NR, HSY; writing review & editing – NR, MJL, CC, BR, HSY.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Acknowledgements

This work was funded by the Canadian Institutes of Health Research (PJT 180387 to HSY), the National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL092321 to HSY), the Natural Sciences and Engineering Research Council of Canada (549297-2019 to MJL), the National Science Foundation (MCB-2309048 to BR), the Agence Nationale de la Recherche (ProteaseInAction and LOR-AI to CC) and the France and Chicago Collaborating in The Sciences (FACCTS) program. This research was enabled in part by support provided by Graham cluster at University of Waterloo (<https://docs.alliancecan.ca/wiki/Graham>) and Digital Research Alliance of Canada (<https://alliancecan.ca>).

References

- M. Mravic, J. L. Thomaston, M. Tucker, P. E. Solomon, L. Liu and W. F. DeGrado, Packing of apolar side chains enables accurate design of highly stable membrane proteins, *Science*, 2019, **363**, 1418–1423.
- J. Lee and W. Im, Role of hydrogen bonding and helix-lipid interactions in transmembrane helix association, *J. Am. Chem. Soc.*, 2008, **130**, 6456–6462.



- 3 P. Lague, M. J. Zuckermann and B. Roux, Lipid-mediated interactions between intrinsic membrane proteins: dependence on protein size and lipid composition, *Biophys. J.*, 2001, **81**, 276–284.
- 4 D. E. Clapham, Calcium signaling, *Cell*, 1995, **80**, 259–268.
- 5 C. Toyoshima, M. Nakasako, H. Nomura and H. Ogawa, Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 Å resolution, *Nature*, 2000, **405**, 647–655.
- 6 C. Toyoshima and H. Nomura, Structural changes in the calcium pump accompanying the dissociation of calcium, *Nature*, 2002, **418**, 605–611.
- 7 D. H. MacLennan and E. G. Kranias, Phospholamban: a crucial regulator of cardiac contractility, *Nat. Rev. Mol. Cell Biol.*, 2003, **4**, 566–577.
- 8 N. Rathod, J. J. Bak, J. O. Primeau, M. E. Fisher, L. M. Espinoza-Fonseca, M. J. Lemieux and H. S. Young, Nothing Regular about the Regulins: Distinct Functional Properties of SERCA Transmembrane Peptide Regulatory Subunits, *Int. J. Mol. Sci.*, 2021, **22**, 8891.
- 9 K. Haghighi, F. Kolokathis, L. Pater, R. A. Lynch, M. Asahi, A. O. Gramolini, G. C. Fan, D. Tsiapras, H. S. Hahn, S. Adamopoulos, S. B. Liggett, G. W. Dorn II, D. H. MacLennan, D. T. Kremastinos and E. G. Kranias, Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human, *J. Clin. Invest.*, 2003, **111**, 869–876.
- 10 J. P. Schmitt, M. Kamisago, M. Asahi, G. H. Li, F. Ahmad, U. Mende, E. G. Kranias, D. H. MacLennan, J. G. Seidman and C. E. Seidman, Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban, *Science*, 2003, **299**, 1410–1413.
- 11 M. M. DeWitt, H. M. MacLeod, B. Soliven and E. M. McNally, Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy, *J. Am. Coll. Cardiol.*, 2006, **48**, 1396–1398.
- 12 K. Haghighi, F. Kolokathis, A. O. Gramolini, J. R. Waggoner, L. Pater, R. A. Lynch, G. C. Fan, D. Tsiapras, R. R. Parekh, G. W. Dorn II, D. H. MacLennan, D. T. Kremastinos and E. G. Kranias, A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 1388–1393.
- 13 P. A. van der Zwaag, I. A. van Rijsingen, R. de Ruiter, E. A. Nannenbergh, J. A. Groeneweg, J. G. Post, R. N. Hauer, I. C. van Gelder, M. P. van den Berg, P. van der Harst, A. A. Wilde and J. P. van Tintelen, Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy, *Neth. Heart J.*, 2013, **21**, 286–293.
- 14 H. S. Young, D. K. Ceholski and C. A. Trieber, Deception in simplicity: hereditary phospholamban mutations in dilated cardiomyopathy, *Biochem. Cell Biol.*, 2015, **93**, 1–7.
- 15 C. A. Trieber, J. L. Douglas, M. Afara and H. S. Young, The effects of mutation on the regulatory properties of phospholamban in co-reconstituted membranes, *Biochemistry*, 2005, **44**, 3289–3297.
- 16 H. K. Simmerman, Y. M. Kobayashi, J. M. Autry and L. R. Jones, A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled-coil pore structure, *J. Biol. Chem.*, 1996, **271**, 5941–5946.
- 17 J. M. Autry and L. R. Jones, Functional Co-expression of the canine cardiac Ca²⁺ pump and phospholamban in *Spodoptera frugiperda* (Sf21) cells reveals new insights on ATPase regulation, *J. Biol. Chem.*, 1997, **272**, 15872–15880.
- 18 R. L. Cornea, L. R. Jones, J. M. Autry and D. D. Thomas, Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers, *Biochemistry*, 1997, **36**, 2960–2967.
- 19 Y. Kimura, K. Kurzydowski, M. Tada and D. H. MacLennan, Phospholamban inhibitory function is activated by depolymerization, *J. Biol. Chem.*, 1997, **272**, 15061–15064.
- 20 S. L. Robia, K. S. Campbell, E. M. Kelly, Z. Hou, D. L. Winters and D. D. Thomas, Forster transfer recovery reveals that phospholamban exchanges slowly from pentamers but rapidly from the SERCA regulatory complex, *Circ. Res.*, 2007, **101**, 1123–1129.
- 21 B. L. Akin, T. D. Hurley, Z. Chen and L. R. Jones, The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum, *J. Biol. Chem.*, 2013, **288**, 30181–30191.
- 22 C. Toyoshima, S. Iwasawa, H. Ogawa, A. Hirata, J. Tsueda and G. Inesi, Crystal structures of the calcium pump and sarcolipin in the Mg²⁺-bound E1 state, *Nature*, 2013, **495**, 260–264.
- 23 A. M. Winther, M. Bublitz, J. L. Karlsen, J. V. Moller, J. B. Hansen, P. Nissen and M. J. Buch-Pedersen, The sarcolipin-bound calcium pump stabilizes calcium sites exposed to the cytoplasm, *Nature*, 2013, **495**, 265–269.
- 24 R. W. Zwanzig, High-temperature equation of state by a perturbation method. I. Nonpolar gases, *J. Chem. Phys.*, 1954, **22**, 1420–1426.
- 25 H. Chen, J. D. C. Maia, B. K. Radak, D. J. Hardy, W. Cai, C. Chipot and E. Tajkhorshid, Boosting Free-Energy Perturbation Calculations with GPU-Accelerated NAMD, *J. Chem. Inf. Model.*, 2020, **60**, 5301–5307.
- 26 J. C. Phillips, D. J. Hardy, J. D. C. Maia, J. E. Stone, J. V. Ribeiro, R. C. Bernardi, R. Buch, G. Fiorin, J. Henin, W. Jiang, R. McGreevy, M. C. R. Melo, B. K. Radak, R. D. Skeel, A. Singharoy, Y. Wang, B. Roux, A. Aksimentiev, Z. Luthey-Schulten, L. V. Kale, K. Schulten, C. Chipot and E. Tajkhorshid, Scalable molecular dynamics on CPU and GPU architectures with NAMD, *J. Chem. Phys.*, 2020, **153**, 044130.
- 27 Y. Kimura, M. Asahi, K. Kurzydowski, M. Tada and D. H. MacLennan, Phospholamban domain Ib mutations influence functional interactions with the Ca²⁺-ATPase isoform of cardiac sarcoplasmic reticulum, *J. Biol. Chem.*, 1998, **273**, 14238–14241.
- 28 E. M. Kelly, Z. Hou, J. Bossuyt, D. M. Bers and S. L. Robia, Phospholamban oligomerization, quaternary structure, and sarco(endoplasmic reticulum calcium ATPase binding measured by fluorescence resonance energy transfer in living cells, *J. Biol. Chem.*, 2008, **283**, 12202–12211.



- 29 C. A. Trieber, M. Afara and H. S. Young, Effects of phospholamban transmembrane mutants on the calcium affinity, maximal activity, and cooperativity of the sarcoplasmic reticulum calcium pump, *Biochemistry*, 2009, **48**, 9287–9296.
- 30 D. K. Ceholski, C. A. Trieber and H. S. Young, Hydrophobic imbalance in the cytoplasmic domain of phospholamban is a determinant for lethal dilated cardiomyopathy, *J. Biol. Chem.*, 2012, **287**, 16521–16529.
- 31 S. Smeazzetto, G. P. Armanious, M. R. Moncelli, J. J. Bak, M. J. Lemieux, H. S. Young and F. Tadini-Buoninsegni, Conformational memory in the association of the transmembrane protein phospholamban with the sarcoplasmic reticulum calcium pump SERCA, *J. Biol. Chem.*, 2017, **292**, 21330–21339.
- 32 D. K. Weber, U. V. Reddy, S. Wang, E. K. Larsen, T. Gopinath, M. B. Gustavsson, R. L. Cornea, D. D. Thomas, A. De Simone and G. Veglia, Structural basis for allosteric control of the SERCA-Phospholamban membrane complex by Ca(2+) and phosphorylation, *Elife*, 2021, **10**, e66226.
- 33 H. S. Young, L. R. Jones and D. L. Stokes, Locating phospholamban in co-crystals with Ca(2+)-ATPase by cryoelectron microscopy, *Biophys. J.*, 2001, **81**, 884–894.
- 34 R. L. Cornea, J. M. Autry, Z. Chen and L. R. Jones, Reexamination of the role of the leucine/isoleucine zipper residues of phospholamban in inhibition of the Ca²⁺ pump of cardiac sarcoplasmic reticulum, *J. Biol. Chem.*, 2000, **275**, 41487–41494.
- 35 S. Lamberth, H. Schmid, M. Muenchback, T. Vorherr, J. Krebs, E. Carafoli and C. Griesinger, NMR Solution Structure of Phospholamban, *Helv. Chim. Acta*, 2000, **83**, 2141–2152.
- 36 R. Verardi, L. Shi, N. J. Traaseth, N. Walsh and G. Veglia, Structural topology of phospholamban pentamer in lipid bilayers by a hybrid solution and solid-state NMR method, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 9101–9106.
- 37 D. H. MacLennan, Y. Kimura and T. Toyofuku, Sites of regulatory interaction between calcium ATPases and phospholamban, *Ann. N. Y. Acad. Sci.*, 1998, **853**, 31–42.
- 38 J. P. Graves, J. O. Primeau, L. M. Espinoza-Fonseca, M. J. Lemieux and H. S. Young, The Phospholamban Pentamer Alters Function of the Sarcoplasmic Reticulum Calcium Pump SERCA, *Biophys. J.*, 2019, **116**, 633–647.
- 39 J. P. Graves, J. O. Primeau, P. A. Gorski, L. M. Espinoza-Fonseca, M. J. Lemieux and H. S. Young, Interaction of a Sarcoplamban Pentamer and Monomer with the Sarcoplasmic Reticulum Calcium Pump, SERCA, *Biophys. J.*, 2020, **118**, 518–531.
- 40 J. P. Graves, C. A. Trieber, D. K. Ceholski, D. L. Stokes and H. S. Young, Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump, *J. Mol. Biol.*, 2011, **405**, 707–723.
- 41 D. L. Stokes, A. J. Pomfret, W. J. Rice, J. P. Graves and H. S. Young, Interactions between Ca²⁺-ATPase and the pentameric form of phospholamban in two-dimensional co-crystals, *Biophys. J.*, 2006, **90**, 4213–4223.
- 42 G. Chu, L. Li, Y. Sato, J. M. Harrer, V. J. Kadambi, B. D. Hoit, D. M. Bers and E. G. Kranias, Pentameric assembly of phospholamban facilitates inhibition of cardiac function in vivo, *J. Biol. Chem.*, 1998, **273**, 33674–33680.
- 43 F. Funk, A. Kronenbitter, K. Hackert, M. Oebbeke, G. Klebe, M. Barth, D. Koch and J. P. Schmitt, Phospholamban pentamerization increases sensitivity and dynamic range of cardiac relaxation, *Cardiovasc. Res.*, 2023, **119**, 1568–1582.
- 44 D. K. Ceholski, C. A. Trieber, C. F. Holmes and H. S. Young, Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase A, *J. Biol. Chem.*, 2012, **287**, 26596–26605.
- 45 T. Wittmann, M. J. Lohse and J. P. Schmitt, Phospholamban pentamers attenuate PKA-dependent phosphorylation of monomers, *J. Mol. Cell. Cardiol.*, 2015, **80**, 90–97.
- 46 C. Toyoshima, M. Asahi, Y. Sugita, R. Khanna, T. Tsuda and D. H. MacLennan, Modeling of the inhibitory interaction of phospholamban with the Ca²⁺ ATPase, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 467–472.
- 47 K. Seidel, O. C. Andronesi, J. Krebs, C. Griesinger, H. S. Young, S. Becker and M. Baldus, Structural characterization of Ca(2+)-ATPase-bound phospholamban in lipid bilayers by solid-state nuclear magnetic resonance (NMR) spectroscopy, *Biochemistry*, 2008, **47**, 4369–4376.
- 48 J. L. Douglas, C. A. Trieber, M. Afara and H. S. Young, Rapid, high-yield expression and purification of Ca²⁺-ATPase regulatory proteins for high-resolution structural studies, *Protein Expression Purif.*, 2005, **40**, 118–125.
- 49 H. S. Young, J. L. Rigaud, J. J. Lacapere, L. G. Reddy and D. L. Stokes, How to make tubular crystals by reconstitution of detergent-solubilized Ca²⁺-ATPase, *Biophys. J.*, 1997, **72**, 2545–2558.
- 50 G. B. Warren, P. A. Toon, N. J. Birdsall, A. G. Lee and J. C. Metcalfe, Reconstitution of a calcium pump using defined membrane components, *Proc. Natl. Acad. Sci. U. S. A.*, 1974, **71**, 622–626.
- 51 B. Webb and A. Sali, Comparative Protein Structure Modeling Using MODELLER, *Curr. Protoc. Bioinf.*, 2016, **54**, 1–37.
- 52 S. Jo, T. Kim and W. Im, Automated builder and database of protein/membrane complexes for molecular dynamics simulations, *PLoS One*, 2007, **2**, e880.
- 53 C. R. Sondergaard, M. H. Olsson, M. Rostkowski and J. H. Jensen, Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values, *J. Chem. Theory Comput.*, 2011, **7**, 2284–2295.
- 54 M. H. Olsson, C. R. Sondergaard, M. Rostkowski and J. H. Jensen, PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions, *J. Chem. Theory Comput.*, 2011, **7**, 525–537.
- 55 A. Sali and T. L. Blundell, Comparative protein modelling by satisfaction of spatial restraints, *J. Mol. Biol.*, 1993, **234**, 779–815.
- 56 A. Fiser, R. K. Do and A. Sali, Modeling of loops in protein structures, *Protein Sci.*, 2000, **9**, 1753–1773.
- 57 M. A. Marti-Renom, A. C. Stuart, A. Fiser, R. Sanchez, F. Melo and A. Sali, Comparative protein structure modeling of



- genes and genomes, *Annu. Rev. Biophys. Biomol. Struct.*, 2000, **29**, 291–325.
- 58 W. Humphrey, A. Dalke and K. Schulten, VMD: visual molecular dynamics, *J. Mol. Graphics*, 1996, **14**, 33–38.
- 59 J. B. Klauda, R. M. Venable, J. A. Freites, J. W. O'Connor, D. J. Tobias, C. Mondragon-Ramirez, I. Vorobyov, A. D. MacKerell Jr. and R. W. Pastor, Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types, *J. Phys. Chem. B*, 2010, **114**, 7830–7843.
- 60 R. B. Best, X. Zhu, J. Shim, P. E. Lopes, J. Mittal, M. Feig and A. D. Mackerell Jr., Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles, *J. Chem. Theory Comput.*, 2012, **8**, 3257–3273.
- 61 V. Ramadoss, F. Dehez and C. Chipot, AlaScan: A Graphical User Interface for Alanine Scanning Free-Energy Calculations, *J. Chem. Inf. Model.*, 2016, **56**, 1122–1126.
- 62 J. C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R. D. Skeel, L. Kale and K. Schulten, Scalable molecular dynamics with NAMD, *J. Comput. Chem.*, 2005, **26**, 1781–1802.
- 63 P. Liu, F. Dehez, W. Cai and C. Chipot, A Toolkit for the Analysis of Free-Energy Perturbation Calculations, *J. Chem. Theory Comput.*, 2012, **8**, 2606–2616.

